Clene Inc. (CLNN) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Clene Inc. on May 5, 2026. The filing discloses the entry into a material definitive agreement regarding a public equity offering. Clene Inc. is a biopharmaceutical company focused on developing cell therapies, with its lead drug candidate being CNM-Au8.
Key Financial Metrics and Transaction Details
- Offering Size: 1,000,000 shares of common stock.
- Offering Price: $7.00 per share.
- Gross Proceeds: $7.0 million.
- Estimated Net Proceeds: Approximately $6.4 million.
- Underwriting Discounts and Commissions: 6.5% of gross proceeds.
- Other Offering Expenses: Approximately $140,000.
- Underwriter: Canaccord Genuity LLC (sole bookrunner).
- Financial Advisors: Maxim Group LLC and D. Boral Capital LLC.
The filing does not provide current revenue, profit, cash flow, or debt metrics as this is a transactional report rather than a periodic financial statement.
Material Changes and Use of Proceeds
The primary material change is the dilution of existing shareholders due to the issuance of new shares. The closing of the offering is expected on May 6, 2026. The Company intends to use the net proceeds for:
- Preparation and filing of the New Drug Application (NDA) for CNM-Au8.
- Conducting and maintaining access to CNM-Au8 in expanded access protocols and a future confirmatory Phase 3 clinical trial.
- Manufacturing expansion.
- Potential future commercialization efforts.
- Additional early-stage research and development activities.
- General corporate purposes.
Guidance, Risks, and Contingencies
Lock-Up Agreements: The Company, its executive officers, directors, and certain affiliated entities have entered into lock-up agreements for 60 days following the date of the Underwriting Agreement. These agreements restrict the sale, short sale, or hedging of the Company's securities without the underwriter's consent.
Contingencies: The closing of the offering is subject to the satisfaction of customary closing conditions.
Risks: The filing notes that the offering is made pursuant to a registration statement on Form S-3 and a prospectus supplement. The report explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Key Facts for Investor Verification
- Verify the actual closing date of the offering (expected May 6, 2026) and the final number of shares issued.
- Confirm the exact net proceeds received after finalizing underwriting discounts and expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification obligations.
- Monitor the progress of the CNM-Au8 New Drug Application filing and Phase 3 trial initiation as funded by these proceeds.
- Check for any subsequent filings regarding the expiration or waiver of the 60-day lock-up period.